Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has today made public the findings it obtained from the Extension Period of the Phase 3 SOLUTION, non-inferiority clinical study in cystic fibrosis among patients struggling with exocrine pancreatic insufficiency .
According to the company’s insiders, that particular extension period had been put in place to serve the need of establishing the long terms effects of Pancreaze and Sollpura through carrying out an observational analysis pertaining the long-term effects.
Anthera’s Chief Medical Officer, William Shanahan is happy about the progress the company has been making lately towards creating top solutions to help patients globally. He expressed his great joy in the fact that the company was overseeing immense success in terms of the continued tolerability as well as maintenance of height and weight in among the various patients diagnosed with Sollpura treated cystic fibrosis patients with EPI during the extension duration and just to make it a little more clearer, increase in height and weight among patients less than 17 years of age.
The changing times in the world we are living in today are coming with new challenges every dawn in terms of developing complications. They are some of these complications that are forcing the research institutions to fold their sleeves in an effort to try and come up with better treatment options to help save the lives the world is loosing as a result of the complications.
Anthera Pharmaceuticals Inc is one of the high end companies that have been doing all within their means to try and develop top solutions to help patients in a great fashion. The company’s top executive added to say that indeed the 20-Week data went quite a long way towards proving the point that indeed Sollpura had whatever it took to provide patients with some alternative to what has already been there- the porcine-based pancreatic enzyme replacement therapies.
It was quite clear from the study that indeed Pancreaze and Sollpura were well tolerated which is indeed new hope for the rest of the patients wherever they may be around the globe. According to some top officials, the company is at the moment laying down strategies that will see the company initiate the Phase 3 trial in a short while.